Abstract
Helicobacter pylori infection is linked to gastritis, ulcersand gastric cancer. Nanomedicine offers a promising solution by utilizing nanoparticles for precise drug delivery, countering antibiotic resistance and delivery issues. Nanocarrierssuch asliposomes and nanoparticles enhance drug stability and circulation, targeting infection sites through gastric mucosa characteristics. Challenges include biocompatibility, stability, scalabilityand personalized therapies. Despite obstacles, nanomedicine's potential for reshaping H. pylori eradication is significant andshowcased in this review focusing on benefits, limitationsand future prospects of nanomedicine-based strategies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
